What's breaking now, across thousands of outlets.
Two companies that have spent decades trying to develop cell therapies for diabetes are set to merge, with the aim of working together to take on a market also being pursued by Vertex and CRISPR ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
BCB-276 is designed to treat diffuse intrinsic pontine glioma (DIPG) by targeting B7-H3, an immune checkpoint protein encoded by the CD276 gene that has been shown to be involved in tumor progression…
Survival rates for childhood cancer now exceed 80%—but this also means more children are living with the long-term emotional and psychosocial impacts of cancer.
A Medicare coverage fight over DCIS biomarker testing raises a critical question: Who decides when the evidence is strong enough to guide radiation treatment?
[Capital FM] Nairobi -- More than half of Kenyans living with metabolic disease do not know they have the disease, while the national caseload is expected to double by 2050, a gap clinicians meeting…
A massive review of psychological research reveals that feeling a sense of purpose is strongly linked to lower levels of depression.
A Seattle biotech trying to flip the script on CAR-T cell therapies — making them akin to small molecules for brain tumors — has put together a megaround with the hopes of becoming a commercial-stage…
